Debiopharm Revenue and Competitors

Lausanne,

Location

N/A

Total Funding

Fintech

Industry

Estimated Revenue & Valuation

  • Debiopharm's estimated annual revenue is currently $98.8M per year.(i)
  • Debiopharm's estimated revenue per employee is $162,500

Employee Data

  • Debiopharm has 608 Employees.(i)
  • Debiopharm grew their employee count by 5% last year.

Debiopharm's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CEOReveal Email/Phone
3
Head Medicinal ChemistryReveal Email/Phone
4
Head Global Program Leadership & Project Management a.i.Reveal Email/Phone
5
Head Strategic PartneringReveal Email/Phone
6
Head Clinical DevelopmentReveal Email/Phone
7
HEAD OF PEOPLE & CULTURE (HR), for BUSINESS DEVELOPMENT and R&DReveal Email/Phone
8
Head Early CommercialReveal Email/Phone
9
Head Clinical Trial SupplyReveal Email/Phone
10
Director, Head Market Intelligence - General Secretary Strategic CommitteesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M26-4%$15.7MN/A
#2
$1.4M21-50%$21.2MN/A
#3
$41.9M2938%$6MN/A
#4
$6M53-22%$216.8MN/A
#5
$0M20%$33.3MN/A
#6
$26M1820%N/AN/A
#7
$30.9M221-26%$64.6MN/A
#8
$28.6M205-22%$46.8MN/A
#9
$249.1M134015%$75MN/A
#10
$12.4M953%N/AN/A
Add Company

What Is Debiopharm?

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners to maximize patient access across the globe. Debiopharm International SA focuses on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide. Debiopharm completed the development and licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If you have interesting molecules and seek a competent and committed partner to develop them, please contact us.

keywords:N/A

N/A

Total Funding

608

Number of Employees

$98.8M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Debiopharm News

2022-04-20 - Endometriosis Drugs Market Size, Scope And Forecast ...

AbbVie, Astellas Pharma, AstraZeneca, Debiopharm Group, Evotec AG, Kissei Pharmaceutical, Neurocrine Biosciences, ObsEva, Pfizer,...

2022-04-06 - DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ...

DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES. USA - English. USA -...

2022-03-30 - VivoSense Announces Closing of $25M Series A Financing

Debiopharm develops, manufactures and invests in innovative therapies and technologies that respond to high unmet medical needs in oncology and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$630.9M21463%N/A
#2
$1383.3M40665%N/A
#3
$1471.5M73215%N/A
#4
$5008.2M1569012%N/A